Researchers used computational modeling to design three novel tripeptides that effectively inhibit the blood pressure-regulating enzyme ACE, confirmed by laboratory testing.
3 novel ACE-inhibiting tripeptidesAll three computationally designed tripeptides showed effective ACE enzyme inhibition when tested in the laboratory, validating the computer-aided design approach.
What the researchers found
Using 3D-QSAR (quantitative structure-activity relationship) modeling with both CoMFA and CoMSIA methods, the researchers developed reliable predictive models for ACE inhibitory peptide activity. The CoMFA model achieved cross-validated R² of 0.660 and predictive R² of 0.667, while CoMSIA achieved 0.646 and 0.645 respectively.
Molecular docking revealed how these peptides bind at the ACE active site, with binding characteristics consistent with the 3D-QSAR contour maps. Based on these computational insights, three novel tripeptides were designed as prospective ACE inhibitors. All three showed effective ACE inhibition when tested experimentally using the DOJINDO ACE Kit-WST reagent, validating the computational design approach.
Why it matters
ACE inhibitors are among the most prescribed medications worldwide for hypertension, but current synthetic drugs can cause unpleasant side effects. Bioactive peptides from food sources have shown ACE-inhibiting potential with fewer side effects, but discovering effective ones by trial and error is slow and expensive. This computational approach accelerates the discovery process, potentially leading to natural peptide-based blood pressure treatments with better safety profiles.
How the study worked
The researchers employed a multi-step computational and experimental approach. First, they built 3D-QSAR models using CoMFA (comparative molecular field analysis) and CoMSIA (comparative molecular similarity indices analysis) based on known ACE inhibitory peptides. Molecular docking was then used to explore how peptides bind at the ACE active site. Based on these computational insights, three novel tripeptides were designed. Finally, the designed peptides were experimentally validated for ACE inhibitory activity using the DOJINDO ACE Kit-WST reagent box.
What this study cannot tell us
The study validated ACE inhibition only in a cell-free enzymatic assay — no cell-based studies, animal models, or human data were reported. The 3D-QSAR models had moderate predictive power (R² ~0.65), leaving room for false positives in peptide design. Oral bioavailability and stability of these tripeptides in the gastrointestinal tract were not assessed. Actual blood pressure-lowering effects in living organisms remain to be demonstrated.
How to read the evidence
This is an early-stage discovery study combining computational modeling with in vitro enzymatic validation. While the computational methods are sound and lab results confirm activity, no biological or clinical data exists. The evidence supports proof-of-concept for the design approach but is far from demonstrating therapeutic value.
When this study was published
Published in 2025, this is a very recent study reflecting current capabilities in computational peptide design and structure-activity modeling.
The bigger picture
Bioactive peptides that inhibit ACE are already found in fermented foods, milk, and fish — and some are marketed as nutraceuticals. This study represents the convergence of computational drug design with peptide science, using modern modeling tools to rationally design peptides rather than discovering them by chance. As computational methods improve, this approach could yield peptide-based blood pressure treatments that bridge the gap between pharmaceutical drugs and functional foods.
Questions still open
- Would these tripeptides survive digestion and reach the bloodstream intact if taken orally?
- How does the ACE inhibitory potency of these designed peptides compare to existing pharmaceutical ACE inhibitors like lisinopril or enalapril?
- Could this computational approach be extended to design peptides targeting other blood pressure-regulating enzymes?
Common questions
What are ACE inhibitory peptides and how do they differ from ACE inhibitor drugs?
Could these computer-designed peptides become blood pressure medications?
Read the original research
Discovery of novel angiotensin-converting enzyme inhibitory peptides by in silico and in vitro studies.
RSC advances, 15(47), 39885-39897
Citation
Jiao, Fenglin; Yang, Jinlin; Wang, Fangfang; Peng, Shanli; Zhou, Bo. (2025). Discovery of novel angiotensin-converting enzyme inhibitory peptides by in silico and in vitro studies.. RSC advances, 15(47), 39885-39897. https://doi.org/10.1039/d5ra06104k